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Poster Session-I 87had AML: 6 induction failures, 6 in refractory relapse, 3 in untreated
relapse, 1 had a second PR, 1 chemo-responsive MDS, 1 in high-risk
CR1 [cytogenetics (CG) -7/t(3;12)]. CG were favorable (n5 1), 8 in-
termediate, and 6 poor prognosis, and in 3 CG were unknown.
GVHD-prophylaxis: tacrolimus/mini-MTX, with rabbit-ATG
(Thymoglobulin) for unrelated/one Ag-mism. related donor trans-
plants.
Results: 1 patient died of pneumonia (day177), and 1 of liver
GVHD (day145) as only treatment-related deaths in the 1st 100
days. Main toxicity was mucositis grade 2–3 (50% of the pts). There
was no significant hepatic/neurologic toxicity. All 22 evaluable pts
engrafted (one progressed by day 130). T-cell chimerism studies
at day130 revealed that groups I1II (lower Clo doses; n 5 10)
had a median of 87% (17–100) donor (T-cell)-derived DNA, groups
III1IV (higher Clo-doses, n5 12) had a median of 100% range (64–
100) donor-DNA. By day1100 both cohorts had a median of 100%
donor-derived DNA, maintained beyond 6 mo. in all evaluable pts. 3
pts are too early; 10 pts have died: PD (5), GVHD 6 infection (4),
and pneumonia (1); 1 AML patient is alive after recurrence and 7
AML and 4 CML patients are alive in CR at a median F/up of 9
mos (4–21).
Conclusions: 1) Clo-Bu-based conditioning appears safe in high-
risk ML pts. 2) there should be no concern about the immunosup-
pressive capability of Clo in this setting 3) additional studies are war-
ranted to evaluate the antileukemic efficacy of this regimen.
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Age (years) 57 (18–76) 56 (18–78) 0.89
Male:Female 186:128 190:124 0.97
Allogeneic:Autologous 77:237 72:242 0.64
Diagnosis 0.91
Myeloma 163 165
NHL 57 64
AML 54 50
Other 40 39
Conditioning regimen 0.97
High-dose Melphalan 163 165
BEAM 45 42
Busulfan-fludarabine 32 33
Reduced-intensity 33 36
Median days to neutrophil
recovery
12 12 0.91
Positive cultures during
neutropenia
97 89 0.49
CoNS/MSSA/MRSA 1
miscellaneous gram-positive
32 33 1
C difficile 24 22 0.88
E faecium (VRE) 9 9 1
Non-VRE Enterococci 3 3 1
Gram-negative bacilli 15 9 0.21
S viridans 11 10 1
Fungus 4 3 1
Positive cultures after
resolution of neutropenia
48 20 \0.001
CoNS/MSSA/MRSA 1
miscellaneous gram-positive
21 9 0.028
C difficile 9 2 0.069
E faecium (VRE) 7 3 0.34
Gram-negative bacilli 8 4 0.38
S viridans 2 1 1
Fungus 1 1 1
VRE surveillance culture
positivity acquired during
hospitalization
56 31 \0.004SUPPORTIVE CARE
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A RANDOMIZED, CONTROLLED TRIAL OF GRAFT-VERSUS-HOST DISEASE
(GVHD) PROPHYLAXIS COMPARING TACROLIMUS AND MYCOPHENO-
LATE MOFETIL TO TACROLIMUS AND METHOTREXATE: ANALYSIS OF
GVHD, RELAPSE AND SURVIVAL
Perkins, J.1, Alsina, M.1, Anasetti, C.1, Ayala, E.1, Fernandez, H.1,
Kharfan-Dabaja, M.1, Ochoa-Bayona, L.1, Perez, L.1,
Raychaudhuri, J.1, Sullivan, D.1, Kim, J.2, Schell, M.2, Field, T.1 1Mof-
fitt Cancer Center, Tampa, FL; 2Moffitt Cancer Center, Tampa, FL
We conducted a single institution, randomized, controlled trial
comparing tacrolimus 1 MTX (TAC/MTX) to tacrolimus 1
MMF (TAC/MMF). Eligible patients (pts) were to receive T-replete
peripheral blood HCT from 10/10 or 9/10 HLA matched donors.
Randomization was stratified based on conditioning regimen inten-
sity. 92 pts were randomized, 45 to TAC/MMF and 47 to TAC/
MTX and were all included in the intent-to-treat (ITT) analysis.
Two pts were not transplanted and one pt withdrew consent prior
to transplant. These pts were excluded in the modified ITT
(MITT) analysis. Pts received TAC 0.03 mg/kg/24hr as a continuous
IV infusion beginning day -3 with doses adjusted to maintain whole
blood levels of 5–15ng/ml. Pts were converted to PO therapy and ta-
pered after 6 months. MTX was given IV at doses of 15mg/m2 day
11 and 10mg/m2 on days 13, 16 and 111. MMF was dosed at 15
mg/kg every 12 hours (up to 3g/d) IV beginning day 0, switched to
PO and continued for 12 months. Acute GVHD (aGVHD) was
graded weekly by standard criteria; chronic GVHD (cGVHD) was
scored monthly based on NIH consensus criteria. The groups
were balanced with respect to age, diagnosis, disease risk, recipi-
ent/donor CMV status, conditioning regimen, donor type and rela-
tion. The cumulative incidences of grade 2–4 and 3–4 aGVHD were
79% and 4% in the TAC/MTX arm and 76% and 14% in the TAC/
MMF arm (MITT; p 5 0.84 and 0.1, respectively). The cumulative
incidence of moderate or severe cGVHD at 6 months was 22% in the
TAC/MTX arm and 26% in the TAC/MMF arm (MITT; p5 0.88).
By ITT analysis, the cumulative incidence of non-relapse mortality
suggested an early difference in favor of TAC/MTX, but at 2 years
it was 28% for TAC/MTX arm compared to 32% for the TAC/
MMF arm (p 5 0.41). The cumulative incidence of relapse was
33% in TAC/MTX arm compared to 18% for the TAC/MMF pts
(p 5 0.06). Overall survival was similar between groups (p 5 0.76;
62% TAC/MTX vs. 66% TAC/MMF at 1 year). We conclude
that MMF was no better than MTX in preventing GVHD and
may perhaps be less effective in preventing more severe forms ofaGVHD. Given the direction of effect we observed in severe
aGVHD, it is unlikely that a larger trial would show benefit for
this endpoint. There was a strong suggestion that relapse was
more frequent after MTX than MMF. The beneficial effect of
MMF on relapse was offset by the early increase in nonrelapse mor-
tality, so that overall survival was unaffected.240
QUESTIONING THE ROLE OF A NEUTROPENIC DIET IN HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Trifilio, S., Pi, J., Holmes Gobel, B., Giel, M., Fishman, M., Masino, K.,
Lucier, E., Korenaga, Y., Mehta, J. Northwestern Memorial Hospital,
Chicago, IL
Neutropenic diets (ND) were developed to decrease gut-derived
infections and are widely used. After finding that there were no clin-
ical trials supporting their use, we discontinued ND in HSCT in late
2006. Our ND excluded fresh fruits and vegetables as well as black
pepper, sushi, deli meats, raw milk products, soft cheeses, raw honey,
miso, and yeast. It was replaced by a modified general diet (Non-
ND) that permits black pepper, fresh fruits and vegetables, and
homemade freshly squeezed juice - but excludes raw tomatoes.
The other restrictions remain. 648 consecutive hospitalized patients
were studied; 314 on ND and 314 after ND discontinuation (non-
ND). All infections occurring during the first hospital stay were
analyzed. All patients received ciprofloxacin 500 mg twice a day,
fluconazole 200 mg daily (autograft) or voriconazole 200 mg twice
daily (allograft), and acyclovir/valacyclovir. The documented infec-
tions included in the analysis comprised positive blood, urine
(.100,000 organisms), BAL, stool, or wound cultures, and clostrid-
ium difficile. As the table shows, there were no differences between
88 Poster Session-Ithe ND and non-ND groups with regards to age, sex, diagnosis and
conditioning regimen, or the number of days to resolution of neutro-
penia. There were no significant differences in the number of posi-
tive cultures between the groups during the neutropenic period.
However, after the resolution of neutropenia, there was a signifi-
cantly higher number of non-enteric gram-positive coccal infections
in the ND group compared to non-ND. There was also a trend to-
wards a higher incidence of C difficile, and a significantly higher in-
cidence of new positive surveillance cultures of VRE on rectal swabs
in the ND group.
Our findings show that there is no apparent benefit associated with
ND. However, more surprising is the finding that some infections
were more common with ND. It could be speculated that the micro-
bial content of the non-ND is higher and, in the setting of broad-
spectrum antimicrobial prophylaxis and therapy, such a diet could
contribute to reduced colonization with virulent microorganisms.
These findings suggest that additional studies are needed to investi-
gate the role of dietary restrictions. If our findings are confirmed,
a major change in an established but non-evidence-based practice
will be needed. An added benefit of the more liberal diet would be
greater palatability - which may contribute to reduction in the use
of TPN and better nutrition.241
SEVERE HEPATOCELLULAR INJURY AFTER HEMATOPOIETIC CELL
TRANSPLANTATION: INCIDENCE, ETIOLOGY, AND OUTCOME
Sakai, M.1, Strasser, S.I.2, McDonald, G.B.1 1Fred Hutchinson Cancer
Research Center, Seattle, WA; 2Royal Prince Alfred Hospital, Sydney,
NSW, Australia
Hepatic complications of transplant are a common cause of mor-
tality. While mild elevations of serum aminotransferase enzymes
(AST, ALT) do not carry an adverse prognosis, this is not the case
with severe hepatocellular injury.
Methods: We reviewed 6,225 consecutive patients transplanted
from 1992–2007 to determine the incidence, causes, and outcomes
of severe hepatocellular injury (defined as serum AST .1,500 U/L
during the time from day 0 to day 100).
Results: Severe hepatocellular injury occurred in 88 patients
(1.4%). Causes were Sinusoidal Obstruction Syndrome (SOS) (n 5
46), hypoxic hepatitis (n 5 33), Varicella Zoster Virus (VZV) hepa-
titis (n 5 4), drug-induced liver injury (N 5 2), and Unknown (n 5
3). The incidence declined from 1.9% in the 1990s to 1.1% recently
(due to a 5-fold decline in SOS as a cause and disappearance of VZV
hepatitis). VZV hepatitis was seen in 4 patients, all before 1999 and
none since. Severe drug injury was attributed to liposomal amphoter-
icin and to carboplatin/etoposide/melphalan, respectively. In
hypoxic hepatitis, peak serum AST was 3,545 U/L (range 1,380–25,
246) within days of shock or prolonged hypoxemia; the case fatality
rate was 88%. In SOS, AST increases occurred 2–6 weeks after diag-
nosis; peak AST was 2,252 U/L (range 1,437–8,281) and the case
fatality rate was 76%, with only total serum bilirubin able to distin-
guish survivors from those who died (2.7 mg/dL vs. 11.3 mg/dL,
respectively, p 5 0.0009).
Conclusions: Hepatic circulatory insults (sinusoidal injury from
the conditioning regimen, hypotension, hypoxemia) and not infec-
tion are the most common cause of severe hepatocellular injury. Al-
though the frequency of severe hepatocellular injury has declined
sharply because of a falling incidence of SOS and VZV hepatitis,
the case fatality rate remains high.242
GENERATION OF HLA-RESTRICTED T-LYMPHOCYTE RESPONSES
AGAINST RECOMBINANT INFLUENZAVIRUS HEMAGGLUTININ A/NEW
CALEDONIA BY AN IN VITRO UMBILICAL CORD BLOOD MODEL OF
DENDRITIC CELL VACCINATION
Decker, W.K.1, Li, S.1, Xing, D.1, Robinson, S.N.1, Yang, H.1,
Steiner, D.1, Shpall, E.J.1, Bollard, C.M.2, Safdar, A.3 1University of
Texas MD Anderson Cancer Center, Houston, TX; 2Baylor College of
Medicine, Houston, TX; 3University of Texas MD Anderson Cancer Cen-
ter, Houston, TX
Introduction: Influenza infection following treatment with
chemotherapy and/or concomitant radiation therapy remains asignificant cause of morbidity among immuncompromised patients
in the hospital setting. Further, such patients tend to seroconvert in-
efficiently and with suboptimal titers following prophylactic vaccina-
tion with either the standard or recombinant influenza vaccines.
Toward the goal of addressing this issue, we have developed an in vi-
tro model of dendritic cell (DC) immunotherapy utilizing DCs gen-
erated from umbilical cord blood (UCB).
Methods: UCB monocytes were harvested by adherence, and
UCB DCs were generated by incubation in GM-CSF and IL-4. Im-
mature DCs were loaded with purified rHA protein [A/New Caledo-
nia (H1N1)], matured with an inflammatory cytokine cocktail, and
used to stimulate autologous T-lymphocytes. T-lymphocyte prim-
ing and development were supported by supplementation with
IL-12, IL-2, IL-7, and IL-15. DC and T-cells were analyzed by
flow cytometry. Antigen specific responses were documented by
IFN-g ELISpot, 51Cr lysis, and tetramer staining. Recombinant
hemagglutinin HLA-restricted peptides were synthesized by
Sigma-Genosys (The Woodlands, Texas). MHC class II DR15-
restricted tetramer was synthesized by Beckman-Coulter (Fullerton, CA).
Results: DCs were primarily of myeloid Langerhans phenotype
(CD11c1, CD14-) and expressed high levels of CD209, HLA-DR
and costimulatory molecules CD80, CD86, and CD83. Primed
and expanded T-cells were predominantly CD62L1CCR7-, indica-
tive of effector status; however, there were also small but distinct
populations CD1271 and CCR71 memory cells. Upon recall with
HA-loaded autologous DC, a 4 to 10-fold increase in the number
of IFN-g producing T-lymphocytes was observed in comparison
to T-cells stimulated with autologous unloaded DCs or allogeneic
DCs loaded with irrelevant antigens. Antigen-specific T-cell func-
tionality was determined by 51Cr lysis assay. Using a peptide library
of predicted HA binding epitopes, we mapped an HA-specific,
DR15-restricted CD4 T-cell epitope (GNLIAPWYAFALSRG)
and documented tetramer-positive CD41 cells in a DR151 back-
ground.
Conclusions: The model demonstrates that HA-specific, HLA-
restricted immune responses may be generated from UCB
lymphocytes and suggests that dendritic cell immunotherapy for
the prevention of influenza might be feasible.243
HUMAN CORONAVIRUS (HCOV) AND RHINOVIRUS (HRHV) INFECTION
AMONG HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) RECIP-
IENTS
Milano, F.1, Campbell, A.P.1,2, Kuypers, J.3, Englund, J.A.2, Callais, C.1,
Corey, L.1, Boeckh, M.1 1Fred Hutchinson Cancer Research Center, Seat-
tle, WA; 2Seattle Children’s Hospital, Seattle, WA; 3University of Wash-
ington, Seattle, WA
Background:Little is known about clinical and virologic manifes-
tations of HCoV and HRhV infections after HCT. HCoV and
HRhV are not usually associated with severe illness but have been
reported to cause pneumonia in immunocompromised patients.
Methods: From Dec. 2005-June 2008, prospective surveillance
was performed on 215 allogeneic HCT recipients for 100 days
post-HCT. Weekly symptom surveys, nasal washes and throat swabs
were collected and samples were tested by RT-PCR. We tested for 4
different types of HCoV (OC43, 229E, HKU1 and NL63).
Results: Among 215 patients, the cumulative incidence estimate
for HCoV infection at day 100 was 11.6 (95% CI, 7.3–15.9) and
for HRhV was 20.9 (95% CI, 15.5–26.4); median time of first detec-
tion was 54 days (range 2–93) and 38 days (0–93), respectively. Inci-
dent virus infections occurred mostly in winter months for HCoV
whereas HRhV infections occurred year-round. Prolonged viral
shedding for $3 months was observed in 6 (13%) patients with
HRhV and in 4 (16%) with HCoV. Twelve of the 25 (48%) subjects
with HCoV and 4 of 45 (9%) with HRhV detections were asymp-
tomatic during every week of virus detection. An additional 3 pa-
tients with .10 samples positive for HRhV reported symptoms
only once during the duration of positivity. Frequently reported
symptoms associated with HRhV detection included rhinorrhea
(52%), cough (32%), shortness of breath (32%), and wheezing
(22%); symptoms reported with HCoV detections were similar to
those when no virus was detected. Of the 45 cases of HRhV infec-
tion, 43 had upper respiratory infection only (URI) and 2 developed
URI plus lower respiratory infection (LRI). None of the 25 cases of
